Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...

The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly's highly-effective Zepbound, but Amgen is taking a ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

at the annual meeting of the American College of Rheumatology (ACR Convergence 2024), Nurix presented a poster entitled "NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR ...

The US regulator has placed oral BTK inhibitor orelabrutinib on partial clinical hold, meaning new patients cannot be enrolled into clinical trials and patients treated with the drug for 70 days ...

aPsoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology and Institute of Medical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie ...

Half a decade has passed since Mindhunter season 2's ending, but Holt McCallany's new Netflix show makes its cancelation hurt all over again.

Pro-Palestinian activists have seemingly put up anti-Israeli posters on the London Underground, accusing Britain of spying on behalf of Israel. An image of the advert, on the Jubilee Line at London ...